Phase III
2 stories
-
healthPan-RAS Inhibitor Shows Survival Gain in Pancreatic Cancer
Daraxonrasib, a pan-RAS inhibitor, demonstrated improved survival and tumor control in advanced pancreatic cancer in early trials.
-
healthUlixacaltamide Shows Sustained Essential Tremor Response in Phase III Trial
New data from a Phase III study presented at AAN 2026 indicates ulixacaltamide maintained response in essential tremor patients, highlighting its potential as a new treatment option.